EUVIMEDEUVIMED entdecken
Crossref

Prognostic impact of lung dose during radiotherapy on patients with lung cancer in the era of immunotherapy

Bing Pang, Elise Liu, Dong-Hui Wang, Xian-Yu Guo, Zheng-Huan Li, Fan-Tu Kong, Xiang-Ying Xu, Xiao-Fen Zhong, Shao-Bo Liang

Clinical and Translational Oncology · 29.10.2026

DOI: 10.1007/s12094-026-04597-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 29.10.2026. Verfasst von Bing Pang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess the prognostic impact of lung dose on non-metastatic lung cancer patients in the era of immunotherapy.

Methods

In this retrospective, single-institution study, 69 patients with non-metastatic lung cancer who received chest radiotherapy (RT) between October 2018 and July 2025 were enrolled, including 45 who received immune checkpoint inhibitors (ICIs) prior to RT. Clinical characteristics, treatments, prognosis, and RT parameters were analyzed.

Results

Of the 69 patients, 46.4% had a mean lung dose (MLD) ≤ 12 Gy. The 2-year progression-free survival (PFS) rate was significantly higher in the MLD ≤ 12 Gy group (80.8% vs. 38.1% for the MLD > 12 Gy group, P = 0.004). Overall survival (OS) rates were 95.8% vs. 48.2% ( P = 0.001), and distant metastasis-free survival (DMFS) rates were 92.3% vs. 65.0% ( P = 0.016). Thirty-two patients (46.4%) had a lung volume receiving ≤ 5 Gy (lung V5) ≤ 50%. Patients with a lung V5 ≤ 50% demonstrated significantly better 2-year PFS (79.2% vs. 40.4%, P = 0.002), OS (90.2% vs. 52.4%, P = 0.002), and DMFS (85.9% vs. 69.3%, P = 0.028). Multivariate analysis confirmed MLD as an independent predictor of PFS and OS. Among patients with an MLD > 12 Gy, the primary causes of death were tumor progression and pneumonitis.

Conclusions

MLD is an independent prognostic predictor in non-metastatic lung cancer. Careful attention to MLD is warranted to optimize survival outcomes and mitigate treatment-related toxicities in the era of immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

IMRTImmune checkpoint inhibitorsLung CancerLung V20Lung V5Mean lung dose

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China.
  • School of Physics and Astronomy, University of St Andrews, North Haugh, St Andrews, KY16 9SS, UK.
  • Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China. Lifz1977@163.com.
  • Biotherapy Centre, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China. zhongxf29@mail.sysu.edu.cn.
  • Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China. liangshb3@mail.sysu.edu.cn.

Zitieren

APA

Pang, B., Liu, E., Wang, D. H., Guo, X. Y., Li, Z. H., Kong, F. T., Xu, X. Y., Zhong, X. F., & Liang, S. B. (2026). Prognostic impact of lung dose during radiotherapy on patients with lung cancer in the era of immunotherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04597-x

Vancouver

Pang B, Liu E, Wang DH, Guo XY, Li ZH, Kong FT, et al. Prognostic impact of lung dose during radiotherapy on patients with lung cancer in the era of immunotherapy. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04597-x

BibTeX
@article{Pang2026,
  author = {Pang, Bing and Liu, Elise and Wang, Dong-Hui and Guo, Xian-Yu and Li, Zheng-Huan and Kong, Fan-Tu and Xu, Xiang-Ying and Zhong, Xiao-Fen and Liang, Shao-Bo},
  title = {Prognostic impact of lung dose during radiotherapy on patients with lung cancer in the era of immunotherapy},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04597-x}
}
Kostenlos starten →